Breaks Categories: News

WednesdayDec 30, 2020 11:33 am

NetworkNewsBreaks – Siyata Mobile Inc. (NASDAQ: SYTA) Adjourns Annual General Meeting

Siyata Mobile (NASDAQ: SYTA, SYTAW), a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers, announces that it has adjourned its annual general shareholder meeting; the meeting has been adjourned until Feb. 23, 2021. The meeting, which convened in Vancouver, British Columbia, on Dec. 29, 2020, was adjourned because new quorum requirements for the meeting were not met. Prior to that date, company shareholders will receive further details regarding the submission of proxies for the adjourned meeting. Proxies that had been received up before the proxy cut-off time for initial meeting were overwhelmingly in favor of…

Continue Reading

WednesdayDec 30, 2020 11:28 am

NetworkNewsBreaks – Creatd Inc. (NASDAQ: CRTD) Announces $7.77M Private Placement

Creatd (NASDAQ: CRTD), the parent company of Vocal, today announced its entry into definitive securities purchase agreements in connection with a private placement of its Series E Convertible Preferred Stock (the "Preferred Stock") and warrants to existing shareholders as well as new institutional investors. Upon the closing of the financing, expected to occur on or prior to Jan. 4, 2021, Creatd expects to receive approximately $7.77 million in gross proceeds, not including any proceeds that may be received upon exercise of the warrants. The company intends to use the net proceeds of the financing to satisfy Nasdaq's stockholders' equity listing…

Continue Reading

WednesdayDec 30, 2020 11:10 am

NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member Dr. Michael Liebowitz authored an article published in CNS Spectrums, a Cambridge University Press journal. The article covers the proposed mechanism of action of VistaGen’s investigational neuroactive nasal sprays, PH94B and PH10, currently in development as potential rapid-onset treatments for anxiety and depression disorders.* The publication details the proposed neural circuits mediating the mechanism of action of pherines, including PH94B…

Continue Reading

WednesdayDec 30, 2020 11:03 am

NetworkNewsBreaks – Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Appoints Amp Energy Founder and CEO to PowerTap Hydrogen Fueling Corp. Advisory Board

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, has announced the appointment of Amp Energy (“Amp”) founder and CEO Dave Rogers to the advisory board of PowerTap Hydrogen Fueling Corp. Before founding Amp, Rogers was the head of carbon markets at Front Street Capital, a $3.5-billion investment manager. In that capacity, he oversaw the origination, sale and trading of carbon credits globally. Rogers believes that hydrogen will play a critical role in the future as the world moves away from fossil-based generation and transportation, and that the proprietary PowerTap technology provides critical advantages over the rest…

Continue Reading

WednesdayDec 30, 2020 10:54 am

NetworkNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Commences FDA EUA Study for POC COVID-19 Testing

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant 1 (aka SARS-CoV-2 VUI 202012/01),”…

Continue Reading

WednesdayDec 30, 2020 10:35 am

NetworkNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Commences Study to Further Knowledge in Psilocybin, Associated Delivery Mechanisms

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushrooms sector, today announced that it is commencing a study on the formulation and manufacturing of psilocybin-based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. According to the update, the study with be conducted at the Toronto Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a key scientific advisor to Pure Extracts. The study will focus on formulating, manufacturing and clinical bioavailability testing of rapid onset psilocybin dosage forms…

Continue Reading

WednesdayDec 30, 2020 10:25 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Q1 Results for Clarmin Explorations

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, on Tuesday announced the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended Oct. 31, 2020. According to the update, a copy of the consolidated financial statements prepared in accordance with International Financial Reporting Standards, as well as the corresponding management’s discussion and analysis for the three months ended Oct. 31, 2020, can be found under Cybin’s profile at www.SEDAR.com. To view the full press release, visit https://nnw.fm/ca5Vh About Cybin Inc. Cybin is a life sciences company advancing psychedelic pharmaceutical treatments…

Continue Reading

WednesdayDec 30, 2020 9:58 am

NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Cancels Upcoming Special Meeting of Stockholders

Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that date and rescheduled for Dec. 30 because a quorum had not been reached. As of the rescheduled date, the required quorum had still not been reached, with only 47% of the outstanding shares having been voted. In cancelling the meeting, the Board of Directors for POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, noted that it was…

Continue Reading

TuesdayDec 29, 2020 12:48 pm

NetworkNewsBreaks – Argo Blockchain (ARBKF) Applies to Trade on US OTCQB Venture Market

Argo Blockchain (OTC: ARBKF), the leading cryptocurrency miner based in the U.K., today announced that it has filed an application with the Financial Industry Regulatory Authority ("FINRA") for the company's shares to be cross-traded publicly on the U.S. OTCQB Venture Market ("OTCQB"), under the ticker "ARBKF," making Argo’s shares more widely available to North American investors. Argo, a global leader in cryptocurrency mining with one of the world’s largest and most efficient operations, is headquartered in London with mining facilities located in strategic locations throughout North America. Its shares are listed on the Main Market of the London Stock Exchange…

Continue Reading

TuesdayDec 29, 2020 11:05 am

NetworkNewsBreaks – Cambium Networks Corporation (NASDAQ: CMBM) Announces $70 Million Secondary Follow-On

Cambium Networks (NASDAQ: CMBM), a provider of wireless networking infrastructure solutions, announced that it has closed an underwritten secondary public offering of 2,500,000 ordinary shares. The shares were sold at $28 per share, and the public offering resulted in approximately $70 million gross proceeds. The shares were sold by Vector Cambium Holdings L.P., which is owned by Vector Capital and certain of its affiliates. In addition to selling the public offering shares, Vector Capital granted the underwriters a 30-day option allowing the  purchase of an additional 375,000 ordinary shares at the public offering price; that price would be less underwriting…

Continue Reading